Omnicell (OMCL)
(Delayed Data from NSDQ)
$29.96 USD
-0.34 (-1.12%)
Updated May 8, 2024 04:00 PM ET
After-Market: $29.95 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Brokerage Reports
Omnicell, Inc. [OMCL]
Reports for Purchase
Showing records 101 - 120 ( 325 total )
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Bull vs. Bear Case; See 110% Upside and 13% Downside from Current Levels
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Reducing Workforce by ~9%; Expect ~7.5% Positive Impact to Annual Adj. Profits
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
3Q Miss; FY Guidance Lowered by 8% on Revenues and 28% on Adj. EBITDA
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Miss + Substantial Guide Down:Valuation Implies Troughing Setup (ex. Great Recession);Remain OW
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Provider: Zacks Investment Research
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Software Expansion Intact; Attractive Entry Point for High-Quality Growth Story
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Reiterated 2025 Revenue Targets, but Margin Targets Lowered ~100 bps
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department